Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 OCT 5 ... and in-vitro Evaluation of 4-Benzylsulfanylpyridine-2-carbohydrazides as Potential Antituberculosis Agents. Archiv der Pharmazie, 2009;342(7):394-404). For additional ... Drug Development, Mycobacteria, Mycobacterium Tuberculosis, Pharmaceuticals, Therapy, Treatment, Charles University. This article was prepared by Biotech ...
2009 OCT 5 ... and antibacterial therapy simultaneously or lower the threshold for early antituberculosis therapy when persistent fever, deteriorated consciousness status, or progression of stage occurs ...
2009 NOV 1 ... and colleagues published their study in International Journal of STD & AIDS (First-line antituberculosis drug resistance prevalence and its pattern among HIV-infected patients in the national ... Bacterial Infection, Mycobacteria, Mycobacterium Tuberculosis, Post-Trials Research, Therapy, Treatment, Virology. This article was prepared by Pharma Investments, ...
2009 OCT 5 ... need to identify indicators of treatment success that will allow safe discontinuation of antituberculosis therapy without an increased risk of the reactivation. This will be of great clinical importance ...
2009 OCT 19 ... in the potent early bactericidal activity of isoniazid during the initial phase of antituberculosis (anti-TB) therapy has been attributed not only to the depletion of logarithmically ...
2009 JUL 13 ... report. "This study describes the susceptibility to second-and third-line antituberculosis drugs among MDRTB cases and treatment outcome of identified XDRTB cases. The results of ... Infection, Multidrug-Resistant Tuberculosis, Mycobacteria, Mycobacterium Tuberculosis, Therapy, Treatment, Virology. This article was prepared by AIDS Weekly editors from ...
2009 SEP 28 ... surviving drug-resistant Mycobacterium aurum: a model for high-throughput antituberculosis drug screening,' have been published. According to recent research from Lucknow, India, ... Chemotherapy, DNA, Drug Development, Drug Discovery, Drug Resistance, Drug Therapy, Drugs, Enzyme Research, Ethionamide, Gene Therapy, Isoniazid, Mycobacterium, ...
2009 AUG 24 ... "Little information exists on the pulmonary pharmacology of antituberculosis drugs. We used population pharmacokinetic modeling and Monte Carlo simulation to ... Chemotherapy, Cutaneous Tuberculosis, Drug Development, Drug Resistance, Drug Therapy, Drugs, Mycobacteria, Mycobacterium Tuberculosis, Pharmaceuticals, Pharmacodynamics, ...
2009 JUL 13 ... "We explored the association between antituberculosis drug pharmacokinetics and treatment outcomes among patients with pulmonary tuberculosis ... Pharmacokinetics, Pyrazinamide, Rifampin, Sexually Transmitted Disease, Therapies, Therapy, Treatment, Viral, Virology. This article was prepared by AIDS Weekly ...
2009 NOV 16 ... including rifampin (rifampicin) and clofazimine, which are first- and second-line antituberculosis drugs. The efflux pump inhibitors carbonyl cyanide m-chlorophenylhydrazone (CCCP) and ... Antimicrobials, Chemotherapy, Clofazimine, Drug Development, Drug Resistance, Drug Therapy, Drugs, Mycobacteria, Mycobacterium Tuberculosis, Pharmaceuticals, Physiology, ...
2009 OCT 5 ... (PMC) is known to develop after antibiotic treatment, but is rarely associated with antituberculosis (antiTB) agents. We report a 28-year-old woman without underlying diseases developing ... Infectious Disease, Pharmaceuticals, Pseudomembranous Enterocolitis, Rifampin, Therapy, Treatment, Tuberculosis, Kaohsiung Medical University. This article was ...
2009 SEP 21 ... are currently renewed efforts to develop drugs that could shorten the duration of antituberculosis therapy. This is best achieved by optimizing the sterilizing effect," scientists in the United ...
2009 NOV 16 ... malachite green and sensitivity to sodium dodecyl sulfate (SDS) detergent and first-line antituberculosis drugs. The lspA mutant has a 10(4)-fold reduction in CFU-forming efficiency on ... Keywords: United States, Palo Alto, Antimicrobials, Chemotherapy, Drug Resistance, Drug Therapy, Enzymes, Mycobacteria, Mycobacterium Tuberculosis, Peptidase, Treatment, Stanford ...
2009 JUL 13 ... United Kingdom, "This study investigated whether serious adverse events (SAEs) during antituberculosis therapy occur more frequently in HIV co-infected patients in a South African population. A ...
2009 JUL 20 ... had multidrug-resistant but non-extensively drug-resistant tuberculosis. Previous antituberculosis treatment (adjusted odds ratio [OR], 10.54 [95% CI, 5.97 to 18.62]), HIV infection (OR, ... Medicine, Multidrug-Resistant Tuberculosis, Mycobacteria, Mycobacterium Tuberculosis, Therapy, Treatment, Virology, University of Tartu. This article was prepared by ...
2009 SEP 28 ... antibiotic class in the United States. They have the potential to become first-line antituberculosis therapy, but the effect of fluoroquinolone use on fluoroquinolone resistance in Mycobacterium ...
2009 OCT 12 ... skin lesion became smaller after prednisolone therapy and was further improved after antituberculosis drugs were added. Reexamination of the previously biopsied skin tissue disclosed ...
